DNTH
Price
$87.38
Change
+$0.01 (+0.01%)
Updated
Jun 23, 04:05 PM (EDT)
Capitalization
4.78B
44 days until earnings call
Intraday BUY SELL Signals
REPL
Price
$11.36
Change
+$0.18 (+1.61%)
Updated
Jun 23, 04:16 PM (EDT)
Capitalization
922.75M
37 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNTH vs REPL

DNTH vs REPL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DNTH vs. REPL commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Buy and REPL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (DNTH: $87.37 vs. REPL: $11.18)
Brand notoriety: DNTH and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 133% vs. REPL: 44%
Market capitalization -- DNTH: $4.78B vs. REPL: $922.75M
DNTH [@Biotechnology] is valued at $4.78B. REPL’s [@Biotechnology] market capitalization is $922.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 0 green FA rating(s).

  • DNTH’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 5 TA indicator(s) are bullish while REPL’s TA Score has 6 bullish TA indicator(s).

  • DNTH’s TA Score: 5 bullish, 4 bearish.
  • REPL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, REPL is a better buy in the short-term than DNTH.

Price Growth

DNTH (@Biotechnology) experienced а +5.89% price change this week, while REPL (@Biotechnology) price change was +24.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

DNTH is expected to report earnings on Aug 06, 2026.

REPL is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($4.78B) has a higher market cap than REPL($923M). DNTH YTD gains are higher at: 112.012 vs. REPL (14.969). DNTH has higher annual earnings (EBITDA): -190.92M vs. REPL (-303.89M). DNTH has more cash in the bank: 1.11B vs. REPL (269M). DNTH has less debt than REPL: DNTH (1.36M) vs REPL (76.3M). DNTH has higher revenues than REPL: DNTH (1.34M) vs REPL (0).
DNTHREPLDNTH / REPL
Capitalization4.78B923M517%
EBITDA-190.92M-303.89M63%
Gain YTD112.01214.969748%
P/E Ratio3.24N/A-
Revenue1.34M0-
Total Cash1.11B269M413%
Total Debt1.36M76.3M2%
FUNDAMENTALS RATINGS
DNTH vs REPL: Fundamental Ratings
DNTH
REPL
OUTLOOK RATING
1..100
2542
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
6100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
3636
P/E GROWTH RATING
1..100
62100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for DNTH (83) in the null industry. This means that REPL’s stock grew somewhat faster than DNTH’s over the last 12 months.

DNTH's Profit vs Risk Rating (6) in the null industry is significantly better than the same rating for REPL (100) in the Biotechnology industry. This means that DNTH’s stock grew significantly faster than REPL’s over the last 12 months.

DNTH's SMR Rating (97) in the null industry is in the same range as REPL (99) in the Biotechnology industry. This means that DNTH’s stock grew similarly to REPL’s over the last 12 months.

DNTH's Price Growth Rating (36) in the null industry is in the same range as REPL (36) in the Biotechnology industry. This means that DNTH’s stock grew similarly to REPL’s over the last 12 months.

DNTH's P/E Growth Rating (62) in the null industry is somewhat better than the same rating for REPL (100) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHREPL
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 19 days ago
86%
Bearish Trend 16 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EINC118.201.55
+1.33%
VanEck Energy Income ETF
AVUS127.780.14
+0.11%
Avantis US Equity ETF
TAXF50.68N/A
N/A
American Century Divers Muncpl Bd ETF
SPCZ26.05-0.17
-0.65%
RiverNorth Ehd PMgr SPAC ETF
HUTG34.20-1.88
-5.21%
Leverage Shares 2X Long HUT Daily ETF

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with XENE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+5.92%
XENE - DNTH
42%
Loosely correlated
+3.55%
REPL - DNTH
41%
Loosely correlated
+9.67%
EDIT - DNTH
41%
Loosely correlated
+3.53%
VYGR - DNTH
40%
Loosely correlated
N/A
ABUS - DNTH
40%
Loosely correlated
-0.88%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+9.67%
IMNN - REPL
57%
Loosely correlated
-1.10%
SNDX - REPL
49%
Loosely correlated
+1.66%
KYMR - REPL
45%
Loosely correlated
+9.97%
NRIX - REPL
43%
Loosely correlated
+6.27%
ZYME - REPL
42%
Loosely correlated
+0.52%
More